Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2008

View Archived Issues

Novel lysosomal enzyme replacement therapy for MPS that crosses the BBB

Studies find little benefit of add-on lamotrigine in refractory schizophrenia patients

Argyll successfully completes first phase of formal proof of concept trial for SF-1019

Novel analgesic agents imparted in recent Vertex and Merck Frosst patents

New therapeutic agents for cardiovascular disorders reported in recent patents

Positive clinical trial results for epilepsy drug rufinamide in mood disorders

Recent patent discloses new therapeutic agents for liver diseases

Bionomics presents R&D update

Amarin provides pipeline update

Novel SMN2 promoter activator by deCODE may be useful in SMA

Genmab reaches two milestones in ofatumumab collaboration with GSK

Threshold provides update on several glufosfamide clinical trials

VIRxSYS signs research agreement with National Heart, Lung, and Blood Institute

Diamyd reports 30-month results from phase IIb study of diabetes vaccine Diamyd

LifeCycle reports interim results from phase II trial of LCP-Tacro in liver transplants

FDA approves Celsion's SPA application for phase III liver cancer trial of ThermoDox

StemCells reports death of patient in phase I clinical trial of HuCNS-SC for NCL

Tripep and Kringle Pharma apply for permission to initiate phase II study of ChronSeal

FDA has not yet made decision on Cardiome's and Astellas' NDA for Kynapid

Trophos completes enrollment of first 90 patients in phase IIa clinical trial of TRO-19622

Serenex and CHDI enter agreement to evaluate Hsp90 inhibitors for Huntington's disease

Synta initiates second phase I clinical trial of novel Hsp90 inhibitor STA-9090 in solid tumors

Positive phase III preliminary results reported for prolonged-release octreotide

Abraxis receives E.U. approval to market Abraxane for metastatic breast cancer

Additional indication for Astellas' Mycamine gets FDA approval

Fast track designation for Sabril in cocaine and methamphetamine dependence treatment

FDA accepts oral fludarabine NDA for review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.